首页> 外文期刊>Current Alzheimer research >Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
【24h】

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective

机译:阿尔茨海默病管理中基于治疗方法的纳米技术:现状和未来的观点

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Alzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD.
机译:背景:阿尔茨海默病(AD),长老之间的认知功能障碍/痴呆状态,其特征是由于病理生理学的不可逆神经变性。 到目前为止,已经开发并用于诊所的具有不同药理的抗AD药物。 然而,这些药物不是治愈性的,只降低了广告相关症状。 治疗结果的改善需要在最佳治疗浓度上以血脑屏障(BBB)靶向中枢神经系统(CNS)。 基于纳米技术的诊断工具,药物载体和Theranostics提供高度敏感的分子检测,有效的药物靶向及其组合。 在过去十年中,在这一领域已经完成了重大作品,我们在广告疗法中看到了非常显着的outocome。 来自有机和无机纳米材料类别的各种纳米颗粒已成功地针对AD进行研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号